Oncology

IBM's Watson takes a dive into the field of genomics to look for actionable cancer mutations

Predicting pancreatic lesion malignancy risk is only an assay away with a PCR-based technique

Discontinuing leukemia treatment without cancer recurrence may be a little safer thanks to ddPCR

Taking on the challenge of opening up new opportunities for retinoblastoma care

We need to reevaluate our approach to kidney disease and its classification

Kidney tumor with dual cell population, features of emperipolesis, cyclin D1 positivity.

A new grading system for prostate carcinoma – and how you can adopt it in your laboratory

Ian Cree, Head, WHO Classification of Tumors Group, International Agency for Research on Cancer

As a qualitative assay, immunohistochemistry does the job. But do we need more?

Are single-cell diagnostics needed to reveal the full picture in breast cancer?